Market revenue in 2023 | USD 8.2 million |
Market revenue in 2030 | USD 20.7 million |
Growth rate | 14.2% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 80.49% in 2023. Horizon Databook has segmented the Italy mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
A wide network of manufacturers & distributors in this region provides essential systems, consumables, and services for miRNA sequencing, which is likely to provide a growth platform for this market. R&D activities are also expected to increase in Italy due to various funds & grants offered by government & nongovernment organizations for medical research.
Presence of favorable government initiatives and policies makes it one of the preferred locations for pharmaceutical and biotechnology manufacturing industries. An increase in research initiatives to develop new applications of miRNA sequencing is likely to drive the overall market in the region.
For instance, the Italian Epigenome Program is sponsored by the Italian government, which comprises two initiatives the Milan Genomic Initiative (MGI) and the Italian Flagship Project EPIGEN. The MGI is a joint operation among IIT (Istituto Italiano di Technologia), IEO (Istituto Europeo di Oncologia), and IFOM (Istituto FIRC di Oncologia Molecolare).
Horizon Databook provides a detailed overview of country-level data and insights on the Italy mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into Italy mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account